TXMD Overview
September 2015
Forward-Looking Statements

This presentation by TherapeuticsMD, Inc. (referred to as “we” and “our”) may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies as well as statements, other than historical facts, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. These statements are often characterized by terminology such as “believe,” “hope,” “may,” “anticipate,” “should,” “intend,” “plan,” “will,” “expect,” “estimate,” “project,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made in light of our managerial experience and perception of historical trends, current conditions, expected future developments and other factors we believe to be appropriate.

Forward-looking statements in this presentation are made as of the date of this presentation, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which may be outside of our control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well our current reports on Form 8-K, and include the following: our ability to maintain or increase sales of our products; our ability to develop, protect and defend our intellectual property; our ability to develop and commercialize our hormone therapy drug candidates and obtain additional financing necessary therefor; the length, cost and uncertain results of our clinical trials; potential adverse side effects or other safety risks that could preclude the approval of our hormone therapy drug candidates; our reliance on third parties to conduct our clinical trials, research and development and manufacturing; the availability of reimbursement from government authorities and health insurance companies for our products; the impact of product liability lawsuits; the influence of extensive and costly government regulation; the volatility of the trading price of our common stock; and the concentration of power in our stock ownership.

PDF copies of press releases and financial tables can be viewed and downloaded at our website: http://www.therapeuticsmd.com/pressreleases.aspx.
Innovative women’s health company exclusively focused on developing and commercializing products for women throughout their life cycles

Drug candidate portfolio is built on patented SYMBODA™ technology, developed to enable new bio-identical hormone combinations, forms and administration routes
### Pipeline Targets Large Markets

#### Pre-Clinical

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
<th>U.S. Market Opp. ($MM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>17β Estradiol in VagiCap™</td>
<td>TX-004HR</td>
<td></td>
<td></td>
<td>$1,546¹</td>
</tr>
<tr>
<td>Combination: 17β Estradiol + Progesterone</td>
<td>TX-001HR</td>
<td></td>
<td></td>
<td>$2,200¹,²</td>
</tr>
<tr>
<td>Oral Progesterone</td>
<td>TX-002HR</td>
<td></td>
<td></td>
<td>$416¹</td>
</tr>
<tr>
<td>Transdermal Progesterone</td>
<td>TX-005HR</td>
<td></td>
<td></td>
<td>$407³</td>
</tr>
<tr>
<td>Transdermal Estradiol + Progesterone</td>
<td>TX-006HR</td>
<td></td>
<td></td>
<td>$81¹</td>
</tr>
</tbody>
</table>

1. Symphony Health Solutions PHAST 2.0 Prescription Monthly Data, 12 months as of June 30, 2015.
3. Estimated U.S. sales, based on half estradiol patch sales.

* In July 2014 we temporarily suspended enrollment in the Spry Trial and, in October we temporarily stopped it in order to update the Phase 3 protocol based on discussions with the FDA. We intend to update the Phase 3 protocol to, among other things, target only those women with secondary amenorrhea due to polycystic ovarian syndrome and to amend the primary endpoint of the trial.
Key Milestones

- **3Q 15**
  - Phase 3 Rejoice Trial last subject last visit

- **4Q 15**
  - Report Phase 3 Rejoice Trial topline results
  - Complete Phase 3 Replenish Trial enrollment
  - NAMS meeting
    - 3 presentations
    - Compounding symposium

- **1H 16**
  - NDA filing TX-004HR
  - Transdermal estradiol and progesterone Phase 1 results

- **2H 16**
  - Phase 3 Replenish Trial last subject out
  - Report Phase 3 Replenish Trial topline results (4Q 16 – 1Q 17)
  - Transdermal estradiol and progesterone Phase 2 results
TX-004HR
VVA Program
Overview – Vulvar and Vaginal Atrophy (VVA)

- Diagnosed in approximately 50% of postmenopausal women
- Most bothersome symptom commonly reported is dyspareunia
- FDA guidance for efficacy requirements:
  - Statistically significant increase in superficial cells
  - Statistically significant decrease in parabasal cells
  - Statistically significant change in vaginal pH
  - Statistically significant reduction in severity of dyspareunia

Healthy Vaginal Tissue

- Superficial cells: >15%
- Intermediate cells: 80%
- Parabasal cells: < 5%

Atrophic Vaginal Tissue

- Superficial cells: <5%
- Intermediate cells: 60%
- Parabasal cells: >30%

VVA Market – Established and Growing

- U.S. sales more than doubled since 2008
- Global market expected to be $2.1 billion in 2022
- Currently no generic competition
- 32 million U.S. women currently experiencing VVA symptoms

<table>
<thead>
<tr>
<th>Product</th>
<th>Compound</th>
<th>TRx¹ 12 Month Rolling (000)</th>
<th>U.S. Sales ($MM)¹ 12 Month Rolling</th>
<th>WAC Price³</th>
</tr>
</thead>
<tbody>
<tr>
<td>Premarin® Cream</td>
<td>Equine vaginal estrogen</td>
<td>1,774</td>
<td>$511</td>
<td>$263.52</td>
</tr>
<tr>
<td>Vagifem® Tablets</td>
<td>Vaginal estradiol</td>
<td>1,851</td>
<td>$463</td>
<td>$306.00*</td>
</tr>
<tr>
<td>Estrace® Cream</td>
<td>Vaginal estradiol</td>
<td>1,751</td>
<td>$406</td>
<td>$240.05</td>
</tr>
<tr>
<td>Osphena® Tablets</td>
<td>Oral SERM</td>
<td>280</td>
<td>$67</td>
<td>$158.00</td>
</tr>
<tr>
<td>Estring®</td>
<td>Vaginal estradiol ring</td>
<td>336</td>
<td>$99</td>
<td>$283.66</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td></td>
<td><strong>5,992</strong></td>
<td><strong>$1,546</strong></td>
<td></td>
</tr>
</tbody>
</table>

1) Symphony Health Solutions PHAST 2.0 Prescription Monthly Data, 12 months as of June 30, 2015.
2) Femring data is excluded due to VMS indication.
3) Medi-Span Price Rx Basic as of 6/10/15. * for 18 tablets ($136.00 WAC for 8 tablets)
4) GlobalData July 2013 report GDHC54PIDR. All trademarks are the property of their respective owners.
VVA Market Dynamics – Ready for New Product

Only 2.3MM U.S. women treated with Rx product

Why?

**Creams**
- Messiness
- Long-term safety
- Dose preparation by user required

**Tablets**
- Long-term safety
- Systemic absorption

Mean treatment duration
- **46 days**
- **103 days**

Women primed for conversion to new product

---

1) IMS Health Plan Claims (April 2008-Mar 2011).
30MM Women with VVA Untreated in U.S.**

- **2.3MM** Rx treated
- **7%** Currently treated
- **32MM** Symptomatic VVA
- **93%** Not treated
- **30MM** Many untreated due to estrogen exposure concerns

**$20 + Billion Opportunity**

**$1.5 Billion**

**$19 Billion**

---


**Not treated with an FDA approved Rx product. OTC products do not effectively treat the underlying pathological causes of VVA and therefore do not halt or reverse the progression of this condition.**
Vagifem® 25 mcg to 10 mcg Market Share

<table>
<thead>
<tr>
<th>Year</th>
<th>2009</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dosage Strength</td>
<td>25 mcg*</td>
<td>10 mcg*</td>
</tr>
<tr>
<td>Market Share¹ (%)</td>
<td>40%</td>
<td>32%</td>
</tr>
</tbody>
</table>

- VVA market TRx increased 15% 2009-2014¹
- Vagifem had an 18% decrease of its own market share moving to 10 mcg only

¹) Symphony Health Solutions PHAST 2.0 Prescription Monthly Data, Annual Data 2009-2014.
*Vagifem 25 mcg was discontinued on July 30, 2010. Vagifem 10 mcg was approved by the FDA November 25, 2009 and began shipping to pharmacies in Q1 2010.

Vagifem is a registered trademark of Novo Nordisk A/S Corp.
**Target Goals**

<table>
<thead>
<tr>
<th>Target Goals</th>
<th>Preliminary Supportive Data</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lower systemic exposure</td>
<td>Phase 1 data with 10 mcg and 25 mcg suggest lower systemic absorption</td>
</tr>
<tr>
<td>Faster onset of action</td>
<td>Phase 2 demonstrated efficacy in 14 days</td>
</tr>
<tr>
<td>New lower effective dose</td>
<td>Phase 3 evaluating broad range of doses, including 4, 10 and 25 mcg</td>
</tr>
<tr>
<td>Improved user experience</td>
<td>Phase 2 showed patient satisfaction; 97% said “easy to use”</td>
</tr>
</tbody>
</table>

*Target Product Profile being evaluated in ongoing Phase 3 Rejoice Trial*
Key Findings

- $T_{\text{max}} \sim 2$ hours with TX-004HR and $\sim 8$ hours with Vagifem
- Systemic absorption AUC (0-24 hours) is 2- to 3-fold lower with TX-004HR relative to Vagifem
TX-004HR Phase 2 Study
Double-blind and Placebo-controlled

Study Design
• 48 postmenopausal women with VVA (24 active, 24 placebo)
• Randomized 1:1 to 10 mcg; 1x daily for 2-week period
• Endpoints measured at 2 weeks; same endpoints to be measured in Phase 3 at 12 weeks

Co-primary Endpoint Results¹
• Increase in superficial cells 35% treatment vs. 4% placebo \((P=0.0002)\)
• Decrease in parabasal cells 54% treatment vs. 4% placebo \((P<0.0001)\)
• Decrease in vaginal pH -0.97 units for treatment vs. -0.34 units for placebo \((P=0.0002)\)
• Numerical reduction of most bothersome symptoms

Secondary Endpoint Results
• Improved patient satisfaction, 97% said easy to use²
• Reduction in atrophic effects on epithelial integrity and vaginal secretions³

TX-004HR Vaginal Estradiol U.S. Launch Timeline

- **Phase 3 Trial**: 12 weeks, ~100 sites
- **Subjects**: ~700 fully enrolled as of June 2015
  - 3 active arms: 4 mcg, 10 mcg, 25 mcg (~175 per arm)
  - 175 placebo
- **FDA required Co-Primary Endpoints for Proposed Indication**
  (from baseline to week 12 versus placebo)
  - Statistically significant increase in the % of vaginal superficial cells
  - Statistically significant decrease in the % of vaginal parabasal cells
  - Statistically significant change in vaginal pH
  - Statistically significant reduction in the severity of dyspareunia

- **Additional Endpoints**
  - PK measures Days 1, 14, 84
  - FSFI (Female Sexual Function Index), acceptability survey

---

1) [NCT02253173](https://clinicaltrials.gov/ct2/show/NCT02253173?term=rejoice&rank=1).
2) Each arm (4 mcg, 10 mcg, and 25 mcg) tested against each co-primary endpoint.
3) The FDA has noted that a single, large, well-controlled clinical trial to support safety and efficacy should be sufficient to submit an NDA for TX-004HR for the proposed indication and that to support the indication in a single trial, evidence of efficacy for a given dose would need to show statistical significance of at least a .01 level.
TX-004HR Phase 3 Trial
Timelines & Milestones

1st Subject Screened
Q3 2014

1st Subject Randomized
Q4 2014

Last Subject Enrolled
Q2 2015

Last Subject Enrolled
Q3 2015

Last Subject Complete*
Q4 2015
(Endometrial biopsy rate limiting)

Last Subject Complete*
Database Lock
Q4 2015

Topline Report

Last Subject Last Visit Details*
• Last subject last visit scheduled for Sept 2015
• Endometrial biopsy (EB) – 3 independent pathologists must read
• If insufficient tissue, repeat EB
• If insufficient tissue on repeat biopsy – transvaginal ultrasound (TVU) assessment
• If endometrium >4 mm on TVU, then hysteroscopy guided biopsy with specimens sent to all three pathologists

** A telephone interview is conducted at Week 14 (15 days after the last dose of investigational product as per study protocol).
TX-001HR
Combination Program
Menopause Overview

Menopause represents the natural life-stage transition when women stop having periods and may result in physical and emotional symptoms.

- Average age of menopause is 51 years\(^1\)
- Hot flashes are due to lower estrogen levels
- Estrogen is given to reduce hot flashes
- Estrogen causes the uterus to thicken (hyperplasia)
- Progesterone is given to non-hysterectomized women to prevent thickening of the uterus

### FDA Approved Hormone Therapy Market Size

<table>
<thead>
<tr>
<th>FDA-Approved Product</th>
<th>U.S. Sales ($MM)</th>
<th>Company</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>17β Estradiol + NETA / DSP</strong>&lt;br&gt;Activella® / FemHRT® / Angeliq®</td>
<td>$37</td>
<td>Warner Chilcott/Bayer/no Novo Nordisk</td>
</tr>
<tr>
<td>Generic 17β + Progestins</td>
<td>$230</td>
<td>TEVA Pharmaceuticals</td>
</tr>
<tr>
<td>Premarin + MPA&lt;br&gt;Prempro® / Premphase®</td>
<td>$339</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Premarin + SERM&lt;br&gt;Duavee®</td>
<td>$19</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Paroxetine&lt;br&gt;Brisdelle®</td>
<td>$36</td>
<td>Noven Pharmaceuticals, Inc</td>
</tr>
<tr>
<td><strong>Total FDA-Approved Oral Combination Sales</strong></td>
<td><strong>$661</strong></td>
<td></td>
</tr>
</tbody>
</table>

1) Symphony Health Solutions PHAST 2.0 Prescription Monthly Data, 12 months as of June 30, 2015.

All trademarks are the property of their respective owners.
Hormone Therapy Market = Two Markets

Total Combination E+P Market

$2.2 billion =

$661MM\textsuperscript{1}

FDA-Approved
No Bio-identical Combinations

$1,500MM\textsuperscript{2}

Compounded Bio-identical
Estradiol / Progesterone

\textsuperscript{1} Symphony Health Solutions PHAST 2.0 Prescription Monthly Data, 12 months as of June 30, 2015.

Number of U.S. Women Using Non-FDA-Approved Compounded HT


Pinkerton, J.V. Menopause Hormone Therapy (MHT) Usage: FDA-Approved MHT has decreased while Compounded non-FDA-approved MHT has increased, *ENDO*, 2015.


* The reported number of annual custom compounded hormone therapy prescriptions is estimated at 26MM to 33MM.
Evidence Supports Bio-identical Progesterone Favorable Clinical Profile Compared to Synthetic Progestins

<table>
<thead>
<tr>
<th>Bio-identical Progesterone</th>
<th>Synthetic Progestins</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Favorable CNS profile</td>
<td>No benefit on sleep properties</td>
<td>Freeman E, et al(^1)</td>
</tr>
<tr>
<td>Favorable breast profile</td>
<td>Increased risk of breast cancer</td>
<td>E3N-EPIC(^2)</td>
</tr>
<tr>
<td>Favorable cardiovascular profile</td>
<td>Increased risk of MI, stroke, VTE</td>
<td>PEPI(^3), ELITE(^5)</td>
</tr>
<tr>
<td>Favorable lipid profile</td>
<td>Less favorable lipid profile effects (cholesterol, LDL, triglycerides)</td>
<td>PEPI(^3)</td>
</tr>
<tr>
<td>Adequate endometrial protection</td>
<td>Adequate endometrial protection</td>
<td>PEPI(^4)</td>
</tr>
<tr>
<td>Low incidence of bleeding</td>
<td>High incidence of bleeding</td>
<td>Lorrain, et al(^6)</td>
</tr>
</tbody>
</table>

Evidence Supports Bio-identical Estradiol Favorable Clinical Profile Compared to Conjugated Estrogens

“CEEs (Premarin) were associated with a higher incidence of venous thrombosis and myocardial infarction than estradiol.”¹
— *Journal of the American Medical Association*, September 2013

“Oral estradiol may be associated with a lower risk of stroke ... compared with conventional-dose oral CEE.”²
— *Menopause*, September 2014

The ELITE trial demonstrated that estradiol is cardioprotective when given during the early postmenopausal years.³
— *Circulation*, November 2014

Cochrane meta analysis demonstrated that estradiol is cardioprotective and reduced overall mortality when given 10 years before the onset of menopause.⁴
— Cochrane Collaboration, 2015

---

2) Shufelt et al. Hormone Therapy Dose, Formulation, Route of Delivery, and Risk of Cardiovascular Events in Women: Findings From the Women’s Health Initiative Observational Study.
Medical Societies Express Concern Over Compounded Hormones

- ACOG and ASRM Committee Opinion states compounded hormones may pose additional risks compared to FDA approved products\(^1\)
  - Lack of Good Manufacturing Practices (GMP)
  - Variable purity
  - Variable content uniformity
  - Variable potency (under/over dose)
  - Not approved for efficacy and safety
  - Lack of stability data

- Medical societies’ global consensus statement declares that the use of custom-compounded hormone therapy is not recommended\(^2\)

---

1) Committee on Gynecologic Practice and the American Society for Reproductive Medicine Practice Committee, Number 532, August 2012 (Reaffirmed 2014, Replaces No. 387, November 2007 and No. 322, November 2005).

2) Villiers, T.J. et. al., Global Consensus Statement on Menopausal Hormone Therapy, Climacteric, June 2013, Vol. 16, No. 3 : Pages 316-337.
Compounding Regulations and Enforcement

Drug Quality and Security Act (DQSA)

- Prohibits compounding of essential copies of an FDA-approved drug except in limited circumstances such as drug shortages
- Anticipate significant impact on compounding upon FDA-approval of first combination hormone therapy product

USP 800 – Hazardous Drugs

- New identification requirements for receipt, storage, mixing, preparing, compounding, dispensing, and administration of hazardous drugs
- Considered “prohibitively expensive” requiring major pharmacy upgrades and renovations to be compliant

[Sources]  
## TX-001HR – Target Product Profile

### Target Goals

<table>
<thead>
<tr>
<th>Meet patient demand for bio-identical hormones</th>
</tr>
</thead>
<tbody>
<tr>
<td>New lower effective dose</td>
</tr>
<tr>
<td>Labeling differentiation</td>
</tr>
<tr>
<td>Leverage data on natural progesterone and 17β estradiol</td>
</tr>
</tbody>
</table>

### Preliminary Supportive Data

<table>
<thead>
<tr>
<th>Potential for FDA-approved first natural estradiol plus natural progesterone combination softgel</th>
</tr>
</thead>
<tbody>
<tr>
<td>Broad range of doses being evaluated in Phase 3</td>
</tr>
<tr>
<td>Bio-identical terminology as both hormones similar to those produced by the ovary</td>
</tr>
<tr>
<td>Inclusion of progesterone/estradiol differences data via label negotiation</td>
</tr>
</tbody>
</table>

*Target Product Profile being evaluated in ongoing Phase 3 Replenish Trial*
TX-001HR Estradiol + Progesterone
U.S. Launch Timeline

- Phase 3 Replenish Trial to enroll 1,750 subjects at ~100 U.S. sites
  - Four active arms (N=400/arm)
    - Estradiol 1 mg/Progesterone 100 mg
    - Estradiol 0.5 mg/Progesterone 100 mg
    - Estradiol 0.5 mg/Progesterone 50 mg
    - Estradiol 0.25 mg/Progesterone 50 mg
  - Placebo arm (N=150)
- 12-month study with 12-week VMS substudy endpoints:
  - Vasomotor substudy: number and severity of hot flashes (4 weeks and 12 weeks)
  - Endometrial safety: incidence of endometrial hyperplasia (12 months)
Early Stage Pipeline: Transdermal Programs
Why Transdermal?

• Transdermal delivery perceived safer due to a lower first-pass effect

• No FDA-approved transdermal progesterone

• New TXMD PK data suggest leveraging solubilized progesterone, show elevated and sustained transdermal levels

• Leveraging this technology creates an opportunity for new progesterone IP, products and novel dosage forms
E+P Topical PK Results

New Formulation PK Data Suggest Sustained 8-hour Duration¹

- Levels in the saliva and capillary samples are higher than in the serum, where it was not detectable¹
- Consistent with published article from Du and Stanczyk 2013²

¹ Data on File, TherapeuticsMD.
Proof Of Concept Efficacy Study

An ovarectomized rat (OVX) is a female rat whose ovaries have been removed.

1) Data on File, TherapeuticsMD.

* p=0.02 vs. Placebo Cream

**** p<0.0001 vs. Placebo Cream
## Transdermal Market Opportunity

<table>
<thead>
<tr>
<th>Product (Combination E+P)</th>
<th>TRx(^1) (000)</th>
<th>U.S. Sales ($MM(^1))</th>
<th>Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>Estradiol/Levonorgestrel (Climara Pro(^®))</td>
<td>111</td>
<td>$23</td>
<td>Bayer</td>
</tr>
<tr>
<td>Estradiol/Norethindrone Acet (CombiPatch(^®))</td>
<td>383</td>
<td>$58</td>
<td>Noven Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td><strong>Total Combination Transdermal Sales</strong></td>
<td><strong>494</strong></td>
<td><strong>$81</strong></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Product (Estradiol Only)</th>
<th>TRx(^1) (000)</th>
<th>U.S. Sales ($MM(^1))</th>
<th>Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>Estradiol (Patch, Gel, Spray) (Alora(^®), Climara(^®), Estraderm(^®), Menostar(^®), Vivelle(^®), Vivelle-Dot(^®), Minivelle(^®); Divigel(^®), Elestrin(^®), Estrogel(^®); Evamist(^®))</td>
<td>5,674</td>
<td>$814</td>
<td>Novartis, Allergan, Meda, Ascend Therapeutics, Lumara Health, Upsher-Smith</td>
</tr>
<tr>
<td><strong>Total Estradiol Transdermal Sales</strong></td>
<td><strong>5,674</strong></td>
<td><strong>$814</strong></td>
<td></td>
</tr>
</tbody>
</table>
Intellectual Property Update
Growing Patent Portfolio

<table>
<thead>
<tr>
<th></th>
<th>Filed</th>
<th>Provisional</th>
<th>Non-Provisional</th>
<th>Issued</th>
</tr>
</thead>
<tbody>
<tr>
<td>U.S.</td>
<td>48</td>
<td>15</td>
<td>22</td>
<td>11</td>
</tr>
<tr>
<td>Ex-U.S.</td>
<td>61</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- Seven new patents issued in 2015 strengthening competitive barriers to entry and building on layered coverage strategies
- Others issued:
  - Field spanning estradiol and progesterone pharmaceutical compositions and methods
  - OPERA reporting and analysis software patent
- Layered patent strategies
  - Field spanning pharmaceutical compositions and methods by family of estradiol and progesterone alone and in combination
  - Siloed strategy for each product
Worldwide Patent Filings*

Strong IP Portfolio with 61 Patents Pending in 12 Jurisdictions Outside the United States

*Not all patent filings filed in all jurisdictions.
Investment Rationale
Investment Rationale

- **Worldwide commercial rights for multiple hormone therapy products in Phase 3 and earlier stages:**
  - Well-known chemical entities with established safety and efficacy thresholds; 505(b)(2)
  - Unique, large, and growing markets with favorable competitive dynamics (DQSA)
  - Additional early stage pipeline candidates
  - Strong foreign IP portfolio with 61 patent applications pending in 12 foreign jurisdictions

- **Growing U.S. commercial business** marketing prescription and OTC prenatal vitamins
  - Customer base of OB/GYNs and other women’s health specialists
  - Recognized by Deloitte Technology Fast 500 as 41st in North America

- **Experienced management team** with proven development and commercial success in women’s health
## TXMD: Financial Snapshot

<table>
<thead>
<tr>
<th>Listing Exchange</th>
<th>NYSE MKT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shares outstanding</td>
<td>177.5 million (as of August 3, 2015)</td>
</tr>
<tr>
<td>Cash</td>
<td>$67.2 million (as of June 30, 2015)</td>
</tr>
<tr>
<td>Financing net proceeds</td>
<td>$32.2 million (offering July 10, 2015)</td>
</tr>
<tr>
<td>Debt</td>
<td>$ 0 million</td>
</tr>
</tbody>
</table>
Thank You!

www.TherapeuticsMD.com
Appendix
Long-Term Growth Opportunity

**DIVERSE PRODUCT PORTFOLIO**
- Two Phase 3 products
  - Trial completion for lead product expected Q4 2015
  - Complete enrollment for second product expected Q4 2015
- Pipeline of 8 novel products
- Expedited and cost effective development – 505(b)(2) pathway
- Unpartnered with worldwide rights

**LARGE UNDERSERVED MARKETS**
- Phase 3 products address ~85 million patients
- Unmet need for safe and effective treatments
- DQSA supports commercial opportunity
- Initial HT market opportunity >$3.5B

**WOMEN’S HEALTH EXPERTISE**
- Experienced clinical team
- Existing commercial infrastructure
- Established customer relationships (OB/GYNs)

**SYMBOLA™ TECHNOLOGY**
- Addresses key formulation and delivery challenges
- VagiCap™ – enhanced gelcap technology
- Transdermal portfolio in development
- 109 patents filed/granted

**EFFICIENT FUNDING**
- No debt
- $200M raised publicly to date
Patient Experience Survey Results Summary

- 97% reported “easy to use”
- 96% reported the TX-004HR softgel (VagiCap™) was “easy to insert”
- 94% reported “convenient to use”
- 0% experienced expulsion of capsule
- >60% “very satisfied”; 8% were “dissatisfied”
- 63% reported quality of life was “somewhat better” to “much better” after only 14 days of use